Back to Search
Start Over
The protective and therapeutic effects of vinpocetine, a PDE1 inhibitor, on oxidative stress and learning and memory impairment induced by an intracerebroventricular (ICV) injection of amyloid beta (aβ) peptide.
- Source :
-
Behavioural brain research [Behav Brain Res] 2020 Apr 06; Vol. 383, pp. 112512. Date of Electronic Publication: 2020 Jan 25. - Publication Year :
- 2020
-
Abstract
- Alzheimer's disease (AD) is a neurodegenerative disease leading to cognitive and memory impairment. This study aimed at investigating the therapeutic and preserving effects of vinpocetine on amyloid beta (Aβ)-induced rat model of AD. Sixty male adult Wistar rats were randomly divided into 6 groups (n = 10 per group) as follows: 1; control, 2; sham, 3; Aβ, 4; pre-treatment (vinpocetine + Aβ): oral gavage administration of vinpocetine at 4 mg/kg for 30 days followed by intracerebroventricular (ICV) injection of Aβ, 5; treatment (Aβ + vinpocetine): Aβ ICV injection followed by vinpocetine administration for 30 days, 6; pre-treatment + treatment (vinpocetine + Aβ + vinpocetine): vinpocetine administration for 30 days before and 30 days after AD induction. Following treatments, the animals' learning and memory were investigated using passive avoidance learning (PAL) task, Morris water maze (MWM), and novel object recognition (NOR) tests. The results demonstrated that Aβ significantly enhanced escape latency and the distance traveled in the MWM, decreased step-through latency, and increased time spent in the dark compartment in PAL. Vinpocetine ameliorated the Aβ-infused memory deficits in both MWM and PAL tests. Administration of vinpocetine in the Aβ rats increased the discrimination index of the NOR test. It also significantly diminished the nitric oxide and malondialdehyde levels and restored the reduced glutathione (GSH) levels. Vinpocetine can improve memory and learning impairment following Aβ infusion due to its different properties, including antioxidant effects, which indicates that vinpocetine administration can lead to the amelioration of cognitive dysfunction in AD.<br />Competing Interests: Declaration of Competing Interest None.<br /> (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Subjects :
- Alzheimer Disease drug therapy
Alzheimer Disease physiopathology
Animals
Cyclic Nucleotide Phosphodiesterases, Type 1 antagonists & inhibitors
Disease Models, Animal
Glutathione drug effects
Glutathione metabolism
Injections, Intraventricular
Learning drug effects
Malondialdehyde metabolism
Memory Disorders
Morris Water Maze Test
Nitrites metabolism
Rats
Spatial Memory drug effects
Alzheimer Disease metabolism
Amyloid beta-Peptides toxicity
Memory drug effects
Oxidative Stress drug effects
Phosphodiesterase Inhibitors pharmacology
Vinca Alkaloids pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1872-7549
- Volume :
- 383
- Database :
- MEDLINE
- Journal :
- Behavioural brain research
- Publication Type :
- Academic Journal
- Accession number :
- 31991177
- Full Text :
- https://doi.org/10.1016/j.bbr.2020.112512